Meeting
2017 Gastrointestinal Cancers Symposium
Evaluation of efficacy of oral administration of pro-drug of triptolide against pancreatic cancer.
Authors
Vikas Dudeja
Vikas Dudeja, Miami, FL
Vikas Dudeja , Nikita Sharma , Shrey Modi , Nipun B. Merchant , Selwyn M. Vickers , Sulagna Banerjee , Ashok Saluja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 296)
DOI
10.1200/JCO.2017.35.4_suppl.296
Abstract #
296
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Synergy of water soluble prodrug triptolide (minnelide) with gemcitabine and nab-paclitaxel in pancreatic cancer.
First Author: Vikas Dudeja
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
First Author: Manish Sharma